PlainPharmaWatch

CMS Open Payments · Program Year 2024

Takeda Pharmaceuticals U.S.A., Inc.

Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 across General Payments, Research, and Ownership to 172,058 physicians and teaching hospitals across 186,599 transactions.

See the rankings → How this is sourced
$199.9M Top 1% payer
All-tracks total
186,599 Top 1% volume
Transactions
172,058 Top 1% reach
Recipients
+$17.3M
General Payments vs PY2023

Takeda Pharmaceuticals U.S.A., Inc. reported $199,919,045.16 across all CMS Open Payments tracks (General + Research + Ownership) to 172,058 physicians and teaching hospitals in Program Year 2024 - ranking #15 of 1,925 reporting manufacturers (1.4% of the all-tracks industry total); General Payments alone were $72,798,431.97, averaging $1.2K per recipient.

How Takeda Pharmaceuticals U.S.A., Inc.'s $199.9M all-tracks total breaks down

Takeda Pharmaceuticals U.S.A., Inc.'s payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

A

100/100

Total payments

A

100/100

Transaction volume

A

100/100

Physician reach

A

100/100

Payment type diversity

A

100/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer takeda-pharmaceuticals-u-s-a-inc Takeda Pharmaceuticals U.S.A., Inc.

$199.9M · #15/1,925 · 1.4% industry · PY2024

  • TOT $199.9M
  • RANK #15
  • SHARE 1.4%
  • TXN 186,599
  • RCP 172,058
  • CAT 9
  • GEN $72.8M
  • ΔGEN +$17.3M
  • TOP1 37.4%
  • PY 2024

Volume peers

Nearest volume peer: BioNTech SE ($204.8M)

GlaxoSmithKline, LLC.$242.1MBioNTech SE$204.8MTakeda Pharmaceuticals U.S.A…$199.9MMedtronic, Inc.$189.9MBoehringer Ingelheim Pharmac…$148.9M
All-tracks payment totals near Takeda Pharmaceuticals U.S.A., Inc. (CMS Open Payments PY2024)

Takeda Pharmaceuticals U.S.A., Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Takeda Pharmaceuticals U.S.A., Inc.'s CMS-reported General Payments increased by $17.3M (+31.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2023: TAKEDA PHARMACEUTICALS U.S.A., INC.PY2024: Takeda Pharmaceuticals U.S.A., Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$55.5MPY2024$72.8M
PY2023
$55,483,057.02
PY2024
$72,798,431.97

What the Data Shows for Takeda Pharmaceuticals U.S.A., Inc.

Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Takeda Pharmaceuticals U.S.A., Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.

"Royalty or License" leads the 9-category general-payment breakdown below at $44.5M (61.1% of General Payments, 27 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Across 9 types of general payments, Takeda Pharmaceuticals U.S.A., Inc.'s largest category was "Royalty or License" at $44.5M - 61.1% of General Payments.

Takeda Pharmaceuticals U.S.A., Inc. reports 9 general-payment categories - the top three are Royalty or License (61.1%), Consulting Fee (14.4%), and Compensation for Services Other Than Consulting (8.7%). The remaining 6 categories make up 15.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

Category breadth matters here: Takeda Pharmaceuticals U.S.A., Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.

How Takeda Pharmaceuticals U.S.A., Inc. divides its payments

How the reported total splits across payment categories

1. Royalty or License$44.5M2. Consulting Fee$10.5M3. Compensation for Services…$6.3M4. Space Rental or Facility …$3.6M5. Food and Beverage$3.5M6. Grant$2.0M7. Travel and Lodging$1.1M8. Education$654.4K9. Charitable Contribution$499.3K
Payment Type Amount Transactions
Royalty or License $44.5M 27
Consulting Fee $10.5M 4,087
Compensation for Services Other Than Consulting $6.3M 985
Space Rental or Facility Fees $3.6M 469
Food and Beverage $3.5M 162,392
Grant $2.0M 27
Travel and Lodging $1.1M 2,754
Education $654.4K 1,310
Charitable Contribution $499.3K 7

Recipient Concentration in General Payments

The five largest recipient relationships account for $44,946,140.80 (61.7%) of $72,798,431.97 in this company's General Payments records across 52,038 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Takeda Pharmaceuticals U.S.A., Inc.

The five named recipients with the highest reported General Payments from this company

Massachusetts General Hospit…$27.2MChildrens Hospital Corporati…$10.1MUniv of Mi Hospitals & Hlth …$4.7MEmory University Hospital$1.7MCleveland Clinic Hospital$1.3M
  1. 1

    Massachusetts General Hospital

    $27,230,462.12 across 6 reported transactions

  2. 2

    Childrens Hospital Corporation

    $10,099,059.07 across 15 reported transactions

  3. 3

    Univ of Mi Hospitals & Hlth Ctrs

    $4,680,763.63 across 18 reported transactions

  4. 4

    Emory University Hospital

    $1,675,055.98 across 8 reported transactions

  5. 5

    Cleveland Clinic Hospital

    $1,260,800.00 across 32 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Takeda Pharmaceuticals U.S.A., Inc. ranks #15 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #826 of 1,838 by HHI (top 45% most concentrated), a wider distribution than most similarly sized payers.

019.238.357.576.71637.81650.11662.51674.91687.3Total payments ($M)Concentration (HHI, 0-10,000)
Takeda Pharmaceuticals U.S.A., Inc. (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Takeda Pharmaceuticals U.S.A., Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Takeda Pharmaceuticals U.S.A., Inc..

Merck Healthcare KGaA

HHI 1648

Aesculap Implant Systems, LLC

HHI 1647

OMNIlife science, Inc

HHI 1654

Marius Pharmaceuticals, Inc

HHI 1645

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Takeda Pharmaceuticals U.S.A., Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Takeda Pharmaceuticals U.S.A., Inc. ranks #15 of 1,925 by all-tracks total payments, led by "Royalty or License".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Takeda Pharmaceuticals U.S.A., Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.